Akanda Corp (AKAN) - Net Assets
Based on the latest financial reports, Akanda Corp (AKAN) has net assets worth $3.30 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.22 Million) and total liabilities ($2.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AKAN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.30 Million |
| % of Total Assets | 53.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Akanda Corp - Net Assets Trend (2020–2024)
This chart illustrates how Akanda Corp's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Akanda Corp for the complete picture of this company's asset base.
Annual Net Assets for Akanda Corp (2020–2024)
The table below shows the annual net assets of Akanda Corp from 2020 to 2024. For live valuation and market cap data, see AKAN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.28 Million | +211.69% |
| 2023-12-31 | $-3.83 Million | -114.23% |
| 2022-12-31 | $26.90 Million | +1321.94% |
| 2021-12-31 | $-2.20 Million | +56.25% |
| 2020-12-31 | $-5.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akanda Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5229636900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $63.32 Million | 1480.62% |
| Other Comprehensive Income | $-1.58 Million | -37.03% |
| Total Equity | $4.28 Million | 100.00% |
Akanda Corp Competitors by Market Cap
The table below lists competitors of Akanda Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Apogee Minerals Ltd
V:APMI
|
$1.51 Million |
|
CONSOLE LABS SA ZY-10
F:9ZK
|
$1.51 Million |
|
Yida China Holdings Ltd
STU:YC2
|
$1.51 Million |
|
TrustBIX Inc
V:TBIX
|
$1.51 Million |
|
GOLDREA RES CORP.
F:GOJ1
|
$1.50 Million |
|
Internet Gold Golden Lines Ltd
TA:IGLD
|
$1.50 Million |
|
BBS-Bioactive Bone Substitutes Oyj
HE:BONEH
|
$1.50 Million |
|
Creative Eye Limited
NSE:CREATIVEYE
|
$1.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akanda Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,828,892 to 4,276,538, a change of 8,105,430.
- Net loss of 4,096,029 reduced equity.
- New share issuances of 10,754,944 increased equity.
- Other comprehensive income decreased equity by 97,818.
- Other factors increased equity by 1,544,333.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.10 Million | -95.78% |
| Share Issuances | $10.75 Million | +251.49% |
| Other Comprehensive Income | $-97.82K | -2.29% |
| Other Changes | $1.54 Million | +36.11% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Akanda Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-69.64 | $57.09 | x |
| 2021-12-31 | $-30.47 | $57.09 | x |
| 2022-12-31 | $310.65 | $57.09 | x |
| 2023-12-31 | $-7.23 | $57.09 | x |
| 2024-12-31 | $4.10 | $57.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akanda Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -95.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -489.57%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.85x
- Recent ROE (-95.78%) is below the historical average (-27.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -111569.88% | 0.00x | 0.00x | $-1.80 Million |
| 2021 | 0.00% | -19625.88% | 0.01x | 0.00x | $-7.91 Million |
| 2022 | -43.34% | -445.00% | 0.07x | 1.45x | $-14.35 Million |
| 2023 | 0.00% | -1494.18% | 0.24x | 0.00x | $-31.89 Million |
| 2024 | -95.78% | -489.57% | 0.11x | 1.85x | $-4.52 Million |
Industry Comparison
This section compares Akanda Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $262,773,237
- Average return on equity (ROE) among peers: -52.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akanda Corp (AKAN) | $3.30 Million | 0.00% | 0.88x | $1.51 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Akanda Corp
As of August 21, 2025, Akanda Corp. was acquired by First Towers & Fiber Corp., in a reverse merger transaction. Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products. The company was incorporated in 2021 and is headquartered in Toronto, Canada.